The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder Maria Carolina Bittencourt GonçalvesRoberta AndrejewCarolina Gubert Leading Article Open access 13 July 2022 Pages: 787 - 801
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments Simon FaissnerRalf Gold Review Article Open access 22 July 2022 Pages: 803 - 817
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia Tanja VeselinovićIrene Neuner Review Article Open access 13 July 2022 Pages: 819 - 858
Antiseizure Drugs and Movement Disorders Michel Sáenz-FarretMarina A. J. TijssenAlfonso Fasano Review Article 21 July 2022 Pages: 859 - 876
The Options for Neuraxial Drug Administration Henning HermannsElke M. E. BosMarkus F. Stevens Review Article Open access 15 July 2022 Pages: 877 - 896
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder Azmi NasserJoseph T. HullAnn Childress Original Research Article Open access 27 July 2022 Pages: 897 - 915
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis Per Soelberg Sorensen Correction 25 July 2022 Pages: 917 - 917